- $17.33m
- $15.31m
- $6.09m
- 94
- 78
- 61
- 92
Annual balance sheet for PharmChem, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2002 December 31st | C2021 December 31st | C2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-Q | PRESS | PRESS |
| Standards: | USG | USG | USG | — | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 4.21 | 2.22 | 3.28 | 1.57 | 1.63 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.79 | 0.918 | 0.581 | 0.636 | 0.727 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 9.82 | 3.22 | 4.08 | 2.64 | 2.65 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 12.1 | 0.001 | 0 | 0.077 | 0.049 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 22.7 | 3.39 | 4.08 | 2.77 | 2.73 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.5 | 0.542 | 0.447 | 0.508 | 0.564 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12.3 | 0.542 | 0.447 | 0.559 | 0.585 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 10.4 | 2.85 | 3.63 | 2.21 | 2.15 |
| Total Liabilities & Shareholders' Equity | 22.7 | 3.39 | 4.08 | 2.77 | 2.73 |
| Total Common Shares Outstanding |